Howie Rosen

Research Statement

Mr. Rosen is interested in the unique aspects of entrepreneurship as it relates to engineering and science-based industries as well as all types of startups in developing economies.

Research Interests

• Entrepreneurship
• Biotechnology
• Pharmaceuticals
• Clean Tech
• Energy
• Developing Economies

Teaching Statement

There are many common themes in the challenges faced by entrepreneurs; my teaching focuses on helping students understand and experience the unique aspects of entrepreneurship as it relates to engineering and science-based industries as well as all types of startups in developing economies.

Bio

Howie Rosen is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), ALCOBRA, LTD (NASDAQ: ADHD), where he has served as Chairman since 2014, ALDEA Pharmaceuticals, Inc., Entrega, Inc., Kala Pharmaceuticals, Inc., where he has served as Chairman since 2014 and PaxVax, Inc., where he has served as Chairman since 2011. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning.

Prior to joining Gilead, Mr. Rosen was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen was a member of the Stanford University Advisory Council on Interdisciplinary Biosciences from 2003 to 2011 and the Stanford School of Engineering Advisory Council from 2004 to 2007. Mr. Rosen is a member of the Biomedical Engineering Advisory Board at City College of New York and the BOD of the MIT Club of Northern California. Previously he was a member of the BODs of CNS Therapeutics, Inc., CoTherix, Inc., NTF Therapeutics, Inc., Pearl Therapeutics, Inc., where he served as interim President and CEO from June 2010 to March 2011, and Pharsight Corporation.

Mr. Rosen is a Lecturer in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), where he is Chair of the Bioengineering Section, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents. Mr. Rosen received an MBA from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has an MS in Chemical Engineering from MIT and he graduated with distinction from Stanford University with a BS in Chemical Engineering.

Academic Degrees

• MBA, Stanford Gradaute School of Business, 1987
• SM Chemical Engineering, MIT, 1982
• BS Chemical Engineering, Stanford University, 1980

Academic Appointments

• Lecturer, Stanford GSB, 2011–present
• Lecturer, Stanford University, Department of Chemical Engineering, 2000–03, 2009-present

Professional Experience

• Chairman, Alcobra, LTD, 2014–present
• Chairman, Kala Pharmaceuticals, 2014–present
• Chairman, PaxVax, Inc., 2011–present
• Interim President & CEO, Pearl Therapeutics, 2010–11
• Vice President Commercial Strategy, Gilead Sciences, 2004-08
• President, ALZA Corporation, 2003–04
• Vice President Product Development, ALZA Corporation, 2002–03

Awards and Honors

• Member, National Academy of Engineering
• Fellow, American Institute of Medical and Biological Engineers
• Henry Ford II Scholar, Stanford Gradaute School of Business
• Arjay Miller Scholar, Stanford Graduate School of Business

Teaching

Degree Courses

2017-18

GSBGEN 314: Creating High Potential Ventures in Developing Economies (Cases and Team Project)

This course addresses the distinctive challenges and opportunities of launching high-potential new ventures in developing economies. Developing economies are attractive targets for entrepreneurs because many are just starting to move up the...

GSBGEN 514: Creating High Potential Ventures in Developing Economies (Cases)

GSBGEN 514 - Creating High Potential Ventures in Developing Economies (2 Units)nnThis course addresses the distinctive challenges and opportunities of launching high-potential new ventures in developing economies. Developing economies are...

STRAMGT 547: Riding The Next Wave in Developing Economies

Today, technology-driven ventures continue to disrupt industries around the world and entrepreneurial ecosystems in developing economies are evolving, creating a better backdrop for entrepreneurs and investors who wish to explore high potential...

2016-17

GSBGEN 314: Creating High Potential Ventures in Developing Economies

This course addresses the distinctive challenges and opportunities of launching high-potential new ventures in developing economies. Developing economies are attractive targets for entrepreneurs because many are just starting to move up the...

GSBGEN 514: Creating High Potential Ventures in Developing Economies

GSBGEN 514 - Creating High Potential Ventures in Developing Economies (2 Units)nnThis course addresses the distinctive challenges and opportunities of launching high-potential new ventures in developing economies. Developing economies are...

STRAMGT 547: Entrepreneurial Opportunities in Developing Economies

As technology-driven ventures are having more and more impact, entrepreneurial ecosystems have been emerging in recent years in developing economies. Following the lead of Silicon Valley, these newly formed industry networks that include...